Brainstorm Cell Therapeutics, Inc.

NASDAQ:BCLI  
3.90
+0.47 (+13.70%)
Earnings Announcements

Brainstorm Cell Therapeutics Announces Third Quarter 2021 Financial Results And Provides A Corporate Update

Published: 11/15/2021 12:13 GMT
Brainstorm Cell Therapeutics, Inc. (BCLI) - Brainstorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update.
Q3 Loss per Share $0.15.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.20

Next Quarter Revenue Guidance is expected to be $9.48 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.